Preventing EBV infection after kidney transplant
Part of Infections clinical trials.
This trial tests if an experimental drug can prevent a common virus (EBV) from causing problems in people who receive a kidney from an EBV-positive donor but have never been exposed to EBV themselves. It aims to reduce the risk of transplant-related complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have never had the EBV virus (tested negative before transplant).
- You are getting a kidney from a donor who has EBV (positive).
- If you can become pregnant, you agree to use highly effective birth control during the study.
- You do not have active cancer or have not had cancer treatment in the past year.
- You do not have other serious infections or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
This study looks at how the immune system responds to BK virus in people who have had a kidney transplant. The virus can sometimes cause problems with the new kidney, so researchers want to compare the immune responses in patients who have the virus with those who don't, and with healthy people.
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
This trial tests a new treatment using specially prepared immune cells (called T cells) that fight the Epstein-Barr virus (EBV). It is for people who have EBV-related conditions, especially after a stem cell or organ transplant, and aims to help control the disease.
This trial tests a vaccine (OSU-2131) that may help prevent cancers caused by the Epstein-Barr virus in people waiting for an organ transplant. The vaccine is designed to train your immune system to fight the virus.
This trial uses a virus called TTV to see if it can help doctors safely adjust immunosuppression drugs in kidney transplant patients. It aims to find a way to lower the risk of rejection while reducing side effects.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.